Juan Carlos Tinoco

Dr. Juan Carlos Tinoco


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2022 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
AGAdriana Guzman-Holst
Adriana Guzman-Holst
MCMaria Yolanda Cervantes-Apolinar
Maria Yolanda Cervantes-Apolinar
JTJuan Carlos Tinoco
Juan Carlos Tinoco
GHGloria C. Huerta
Gloria C. Huerta
Introduction The risk of herpes zoster (HZ) increases with age. In countries with an ageing population such as Mexico, a rise in the risk of HZ and complications is expected. The goal of this study was to provide an updated estimate of the potential burden of HZ and associated complications in Mexico. Methods A retrospective database study was performed using data from the national surveillance database of the Ministry of Health (Secretaría de Salubridad y Asistencia/Dirección General de Información en Salud). HZ cases and associated complications were identified via the International Classification of Diseases 10th Revision codes. Emergency room (ER) visits, hospitalizations, and deaths were extracted and analyzed by age group and year. The observation period was between 2011 and 2020 for ER visits and hospitalizations and between 2011 and 2019 for deaths. Cumulative incidence per 1000 people and case fatality rate were estimated. Results During the observation period, 53,030 ER visits, 4172 hospitalizations, and 263 deaths due to HZ were reported nationwide. The cumulative incidence of HZ based on ER visits was 1.04 per 1000 people aged ≥ 50 years but increased in older age groups (1.47 per 1000 people aged ≥ 65 years). The most common complications were neuralgia (10.9%), ocular disease (7.0%), meningoencephalitis (2.9%), and disseminated disease (3.1%). Patients ≥ 65 years accounted for 37% of hospitalizations and 81% of deaths. Conclusion In Mexico, HZ and its complications impose a considerable burden on the population and the healthcare system. Prospective surveillance studies are required to obtain an accurate picture of the current epidemiology of HZ in Mexico and to estimate the benefits of future vaccination strategies against HZ.

6 November 2025 in Journal of Infection and Public Health
Verified
Journal Article
Open access
MCMaría Noemí Carnalla-Barajas
María Noemí Carnalla-Barajas
ASAraceli Soto-Noguerón
Araceli Soto-Noguerón
FSFortino Solorzano Solórzano Santos
Fortino Solorzano Solórzano Santos
MMMercedes Macías-Parra
Mercedes Macías-Parra
VDVirginia Díaz-Jiménez
Virginia Díaz-Jiménez
GEGabriela Echániz-Aviles
Gabriela Echániz-Aviles
Streptococcus pneumoniae remains a leading cause of bacterial meningitis in children, despite widespread use of pneumococcal conjugate vaccines (PCVs). This study evaluates changes in serotype distribution and antimicrobial resistance (AMR) in pediatric pneumococcal meningitis in Mexico, before and after PCV introduction. We conducted a prospective analysis of pneumococcal isolates collected from children aged 0-17 years diagnosed with meningitis between 1993 and 2024 through the GIVEBPVac surveillance network. Serotyping was performed using the Neufeld-Quellung reaction, and AMR profiles were determined by broth microdilution following CLSI guidelines. Temporal trends were assessed by Poisson regression and stratified by vaccination period (pre-PCV, PCV7/PCV10, and PCV13). A total of 575 pneumococcal meningitis isolates were analyzed. The proportion of PCV13 serotypes declined from 77.2 % in the pre-PCV period to 33.3 % in the PCV13 period, while non-vaccine serotypes rose to 66.7 %. Serotypes 14, 6B, 19 F, and 23 F were predominant before PCV introduction. In the PCV13 era, serotypes 19 A and 15B increased in frequency, while 23B and 6 C emerged among non-vaccine serotypes. Resistance to cefotaxime increased from 22.8 % in the pre-PCV to 30.4 % during the PCV13 period. The overall case fatality rate was 8 %. PCVs significantly reduced the burden of pneumococcal meningitis in Mexican children. However, the emergence of non-vaccine serotypes and the persistence of serotype 19 A highlights the need for continued surveillance and evaluation of higher-valent vaccines to inform future immunization strategies.

21 December 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
MCMaría Yolanda Cervantes-Apolinar
María Yolanda Cervantes-Apolinar
AGAdriana Guzman-Holst
Adriana Guzman-Holst
ASAbiel Mascareñas De Los Santos
Abiel Mascareñas De Los Santos
AMAlejandro Macias
Alejandro Macias
ÁCÁlvaro Cabrera
Álvaro Cabrera
GHGloria C. Huerta
Gloria C. Huerta
Herpes zoster (HZ) is a common disease in older adults and immunocompromised patients, and is frequently associated with long-term complications that impact quality of life. Fortunately, more than one vaccine against HZ is now available in Mexico. Two expert consensus groups discussed adult vaccination strategies in Mexico, focusing on HZ in older adults and immunocompromised individuals; their insights are reported here. HZ is usually treated inappropriately in Mexico. Late diagnosis and suboptimal management are common, as is a lack of treatment options, particularly for pain, which is often unresponsive to standard painkillers. Improving vaccination rates against HZ in Mexico is therefore important, but several barriers to HZ vaccination exist. It is not included in the national vaccination schedule, where included vaccines usually have higher coverage. Actions to overcome barriers include improving awareness of HZ and vaccine availability, developing and promoting guidelines and recommendations for vaccination, and expanding access and infrastructure for vaccination.

14 January 2026 in BMC Pregnancy and Childbirth
Verified
Journal Article
Open access
PDF file
ATAntonella Nadia Tullio
Antonella Nadia Tullio
EYEmad Yanni
Emad Yanni
CCConrado Milani Coutinho
Conrado Milani Coutinho
LSLavitha Sivapatham
Lavitha Sivapatham
CLChristine Mui Fong Lee
Christine Mui Fong Lee
GSGaël Dos Santos
Gaël Dos Santos
Background: Maternal vaccines can reduce the burden of diseases for both mother and neonate. The development and implementation of such vaccines require a thorough interpretation of safety data and standardized disease case definitions. This study aimed to evaluate the current rates for adverse pregnancy outcomes, maternal and neonatal events of interest (EOIs) that will be informative for preparing future phase III clinical trials on maternal vaccines conducted in low- and middle-income countries and further assisting in safety data interpretation (e.g., monitoring potential safety signals in clinical trials, and/or helping with the causality assessments of adverse events following immunization). Methods: We performed a prospective cohort study on healthy 18–45-year-old women, with singleton, low-risk pregnancies, with a gestational age of ≥24 0/7 weeks at enrollment and ≤27 6/7 weeks at first visit, and their neonates. The study was conducted between 2019–2021 in 10 countries that were considered low- and middle-income countries by the World Bank Group at the time the study was designed. All pregnancy-related outcomes and maternal EOIs occurring from enrollment up to 42 days post-delivery and neonatal EOIs occurring within the first 28 days after birth were recorded. Results: Of 2311 pregnant women and 2181 neonates enrolled, 2222 and 2094 were included in the analyses, respectively. Most livebirths (2088 [94.0%]) were without apparent congenital anomalies. Preterm delivery (166 [7.5%]), non-reassuring fetal status (137 [6.2%]), and hypertensive disorders of pregnancy (125 [5.6%]) were the most frequently reported EOIs related to pregnancy. The most frequent neonatal EOIs were low birthweight (including very low birthweight) (156 [7.4%]), preterm birth (141 [6.7%]), small for gestational age (111 [5.3%]), and congenital anomalies (103 [4.9%], including mainly major external structural defects, as well as detected internal and functional defects). Overall, there were similar frequencies in pregnancy outcomes, pregnancy-related and neonatal EOIs across countries, although some variation in the reporting rate was noted. Conclusion: This multicountry study contributes to establishing the most recent background rates for pregnancy outcomes, maternal and neonatal EOIs in low- and middle-income regions. The clinical relevance in the context of the safety assessment in future trials will be applied. Trial registration: NCT03614676 (03/08/2018).

9 July 2026 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
JTJuan Carlos Tinoco
Juan Carlos Tinoco
MGMarivel Guereca
Marivel Guereca
JOJennifer Onwumeh-Okwundu
Jennifer Onwumeh-Okwundu
YMYolanda Martinez-Lopez
Yolanda Martinez-Lopez
PRPatricia Rodríguez-Zulueta
Patricia Rodríguez-Zulueta
MFMark A. Fletcher
Mark A. Fletcher
Background: Community-acquired pneumonia (CAP) in adults represents a significant burden on the healthcare system in México, particularly among high-risk groups. Materials and methods: Adults hospitalized with chest X-ray-confirmed CAP (2018–2021) were prospectively enrolled across four cities in México (Mexico City, Durango, Mérida, and Tijuana). Urine samples were screened for Streptococcus pneumoniae ( S. pneumoniae ) using the BinaxNOW ® test and serotype-specific urine antigen detection (ssUAD) assays targeting 24 serotypes, and blood was obtained for pneumococcal culture. Results: Of the 1,275 patients screened for CAP, 389 had clinically or radiologically confirmed CAP (65.3% male; median age, 60 years; 39.3% aged ≥65 years). Pneumococcal CAP (pCAP) was identified in 12.1% of patients (47/389; 95% CI: 9.01–15.74). Based on CRB-65 scores, pCAP was more frequent among high-risk CAP patients (25.5%, 12/47) than among low- or moderate-risk CAP patients (10.2%, 35/342). Nevertheless, the 30-day mortality rate was 34.0% among pCAP patients versus 29.5% among S. pneumoniae -negative CAP patients. The most prevalent serotypes were 3 (13.0%), 6A (8.7%), and 19A (8.7%), and PCV20 would have covered 54.3% (25/46) of pCAP serotypes identified in this study. Conclusion: During the study period, CAP was associated with a substantial mortality burden among hospitalized adult patients in México, with pCAP more frequent among high-risk patients. These findings underscore the needs for enhanced diagnostic approaches and risk group-targeted adult pneumococcal vaccination programs.